Neoadjuvant Tislelizumab, Gemcitabine, Cisplatin and S-1 for Resectable High-risk Cholangiocarcinoma
Clinical trial NCT06903273 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06903273
- Sponsor
- National Cheng-Kung University Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2028-07-01
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.